{"filing":{"accession_number":"0001654954-26-009093","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"a9580z.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426009093/a9580z.htm"},"events":[{"id":37027,"run_id":34128,"accession_number":"0001654954-26-009093","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The 6-K discloses FDA accelerated approval of Ultomiris (ravulizumab) for a new indication—reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)—based on positive Phase III interim trial results showing a 43.4% reduction in proteinuria versus placebo. This is a material regulatory and commercial milestone for AstraZeneca's rare disease portfolio, representing the fifth approved indication for Ultomiris and expanding its addressable market. While not a discrete M\u0026A, financial obligation, or executive event, it is a significant operational/commercial achievement that would affect a reasonable investor's assessment of the company's pipeline and revenue prospects.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-10-22","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":41608,"accession_number":"0001654954-26-009093","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The 6-K discloses FDA accelerated approval of Ultomiris (ravulizumab) for a new indication—reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)—based on positive Phase III interim trial results showing a 43.4% reduction in proteinuria versus placebo. This is a material regulatory and commercial milestone for AstraZeneca's rare disease portfolio, representing the fifth approved indication for Ultomiris and expanding its addressable market. While not a discrete M\u0026A, financial obligation, or executive event, it is a significant operational/commercial achievement that would affect a reasonable investor's assessment of the company's pipeline and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:11:37.186358+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-10-22"}]}